Citations

Clear

299 citation(s) found for "Solomon, B".

77 HELIOS-A: 18-MONTH EXPLORATORY CARDIAC RESULTS FROM THE PHASE 3 STUDY OF VUTRISIRAN IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS
Kale, Parag , DiCarli, Marcelo F., Solomon, Scott, Chen, Chongshu , Arum, Seth, Vest, John, Grogan, Martha , Gillmore, Julian D , Mussinelli, Roberta , Garcia-Pavia, Pablo , Gillmore, Julian D. , Berk, John L. , Maurer, Matthew J. , Conceição, Isabel , Vest, John

Mayo Clinic

European Heart Journal Supplements | December 15, 2022 | Volume: 24 | Issue: Supplement_K | Pages: No page available

10.1093/eurheartjsupp/suac121.654 Get It

Abstract Background Hereditary transthyretin-mediated (hATTR) amyloidosis, also known as ATTRv amyloidosis, is a fatal, multisystem disease that presents with progressive polyneuropathy and/or cardiomyopathy. HELIOS-A (NCT03759379) assessed the efficacy of vutrisiran, an investigational RNA interference therapeutic, in patients with hATTR amyloidosis with polyneuropathy. Purpose To evaluate the effect of 18 months of vutrisiran treatment on exploratory cardiac endpoints in the HELIOS-A Phase 3 study. Methods Patients were randomised (3:1) to vutrisiran (25 mg SC, q3m) or patisiran (0.3 mg/kg IV, q3w), a reference comparator. The APOLLO placebo group (n=77) was an external control. Primary endpoint was change from baseline in the modified Neuropathy Impairment Score +7 (mNIS+7) at 9 months, vs. external placebo. Exploratory cardiac endpoints included change from baseline in NT-proBNP levels, echocardiography parameters, and technetium (Tc) scintigraphy parameters at 18 months. A prespecified cardiac subpopulation was included (baseline left ventricular wall thickness ≥1.3 cm and no medical history of aortic valve disease or hypertension). Results HELIOS-A enrolled 164 patients and the primary endpoint was met. In the cardiac subpopulation (n=40/122 vutrisiran; n=36/77 placebo), 18 months of vutrisiran treatment significantly improved NT-ProBNP levels vs. external placebo (adjusted geometric fold change ratio: 0.49; p=0.0004) and demonstrated a trend towards improvement in echocardiographic parameters vs. external placebo (including a significant difference in cardiac output [least squares mean difference: 0.41; p=0.043]). Of the 122 vutrisiran-treated patients, 99mTc scintigraphy assessment was captured for 64 vutrisiran-treated patients at baseline, 35 (54.7%) of whom had Perugini grade ≥2 (moderate/intense) cardiac uptake of 99mTc. Among patients with evaluable scintigraphy parameters repeated at 18 months (evaluable patients), heart-to-contralateral lung ratio and normalised LV total uptake on scintigraphy improved (decrease from baseline) in 64.6% (31/48) and 68.1% (32/47), respectively, at 18 months. Of the evaluable patients, 28.1% (16/57) had an improvement (reduction from baseline) in Perugini grade of cardiac uptake, 68.4% (39/57) had no change in grade, and 3.5% (2/57) worsened in grade. Of evaluable patients with baseline Perugini grade ≥2, the proportion with improvement in heart-to-contralateral lung ratio and normalised LV total uptake was 76.9% (20/26) and 100% (25/25) respectively. No cardiac safety concerns were identified with vutrisiran treatment. Conclusions In this exploratory analysis, vutrisiran treatment was associated with a positive impact on NT-ProBNP levels and echocardiographic parameters vs. external placebo in the cardiac subpopulation. Vutrisiran treatment also reduced cardiac uptake of 99mTc potentially suggesting reduction in cardiac amyloid, although the clinical significance of this is not yet clear.
Clinician and Algorithmic Application of the 2019 and 2022 Society of Cardiovascular Angiography and Intervention Shock Stages in the Critical Care Cardiology Trials Network Registry
Patel, Siddharth M. , Berg, David D. , Bohula, Erin A. , Baird-Zars, Vivian M., Barnett, Christopher F. , Barsness, Gregory W. , Chaudhry, Sunit‐Preet , Daniels, Lori B. , Diepen, Sean van , Goldfarb, Michael , Katz, Jason N. , Kenigsberg, Benjamin B. , Lawler, Patrick R. , Miller, P. Elliott , Papolos, Alexander , Park, Jeong‐Gun , Prasad, Rajnish, Teuteberg, Jeffrey J. , Investigators, on behalf of the CCCTN, Goldfarb, Michael , van Diepen, Sean , Goldfarb, Michael , Jentzer, Jacob C , Lawler, Patrick , Miller, P Elliott , Potter, Brian J , Singam, N Sarma V , Solomon, Michael A , Teuteberg, Jeffrey J , Morrow, David A , Goldfarb, Michael , Daniels, Lori B , Bohula, Erin A , Berg, David , Patel, Siddharth M , Ghafghazi, Shahab , Jentzer, Jacob C. , Prasad, Rajnish, Singam, Narayana Sarma V. , Sinha, Shashank S , Solomon, Michael A. , Morrow, David A. , Investigators, on behalf of the CCCTN

Mayo Clinic

Circulation: Heart Failure | December 2, 2022 | Volume: 16 | Issue: 1 | Pages: No page available

10.1161/circheartfailure.122.009714 | PMID 36458542 Get It

Background: Algorithmic application of the 2019 Society of Cardiovascular Angiography and Intervention (SCAI) shock stages effectively stratifies mortality risk for patients with cardiogenic shock. However, clinician assessment of SCAI staging may differ. Moreover, the implications of the 2022 SCAI criteria update remain incompletely defined. Methods: The Critical Care Cardiology Trials Network is a multicenter registry of cardiac intensive care units (CICUs). Between 2019 and 2021, participating centers (n=32) contributed at least a 2-month snapshot of consecutive medical CICU admissions. In-hospital mortality was assessed across 3 separate staging methods: clinician assessment, Critical Care Cardiology Trials Network algorithmic application of the 2019 SCAI criteria, and a revision of the Critical Care Cardiology Trials Network application using the 2022 SCAI criteria. Results: Of 9612 admissions, 1340 (13.9%) presented with cardiogenic shock with in-hospital mortality of 35.2%. Both clinician and algorithm-based staging using the 2019 SCAI criteria identified a stepwise gradient of mortality risk (stage C–E: 19.0% to 83.7% and 14.6% to 52.2%, respectively; P trend <0.001 for each). Clinician assignment of SCAI stages identified higher risk patients compared with algorithm-based assignment (stage D: 49.9% versus 29.3%; stage E: 83.7% versus 52.2%). Algorithmic application of the 2022 SCAI criteria, with incorporation of the vasoactive-inotropic score, more closely approximated clinician staging (mortality for stage C-E: 21.9% to 70.5%; P trend <0.001). Conclusions: Both clinician and algorithm-based application of the 2019 SCAI stages identify a stepwise gradient of mortality risk, although clinician-staging may better allocate higher risk patients into advanced SCAI stages. Updated algorithmic staging using the 2022 SCAI criteria and vasoactive-inotropic score further refines risk stratification.
Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary
Solomon, Scott R. , Arnason, Jon , Johnston, Patrick B., Glaß, Bertram , Mielke, Stephan , Mutsaers, Pim , Hernandez‐Ilizaliturri, Francisco J. , Lunning, Matthew A. , Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro , Mielke, Stephan , Abramson, Jeremy S. , Johnston, Patrick B. , Bachanová, Veronika , Ibrahimi, Sami , Izutsu, Koji , Morschhauser, Franck , Kamdar, Manali

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1581-1583

10.1182/blood-2022-159702 Get It

Autoimmune Encephalitis Misdiagnosis in Adults
Geschwind, Michael D. , López‐Chiriboga, A. Sebastian , Blackburn, Kyle , Turaga, Sanchit, Binks, Sophie , Day, Gregory S. , Rodenbeck, Stefanie, Clardy, Stacey , Solomon, Andrew , Pittock, Sean J. , Dubey, Divyanshu , Ζεκερίδου, Αναστασία , Toledano, Michel , Turner, Lindsey E., Vernino, Steven , Irani, Sarosh R. , Pittock, S J , Irani, Sarosh R , Clardy, Stacey L , Day, Gregory S , Dubey, Divyanshu , Binks, Sophie N M , Vernino, Steven , Flanagan, Eoin P. , Zitser, Jennifer , Gelfand, Jeffrey M. , Dunham, Steven , McKeon, Andrew

Mayo Clinic

JAMA Neurology | November 28, 2022 | Volume: 80 | Issue: 1 | Pages: 30

10.1001/jamaneurol.2022.4251 | PMID 36441519 Get It

ImportanceAutoimmune encephalitis misdiagnosis can lead to harm.ObjectiveTo determine the diseases misdiagnosed as autoimmune encephalitis and potential reasons for misdiagnosis.Design, Setting, and ParticipantsThis retrospective multicenter study took place from January 1, 2014, to December 31, 2020, at autoimmune encephalitis subspecialty outpatient clinics including Mayo Clinic (n = 44), University of Oxford (n = 18), University of Texas Southwestern (n = 18), University of California, San Francisco (n = 17), Washington University in St Louis (n = 6), and University of Utah (n = 4). Inclusion criteria were adults (age ≥18 years) with a prior autoimmune encephalitis diagnosis at a participating center or other medical facility and a subsequent alternative diagnosis at a participating center. A total of 393 patients were referred with an autoimmune encephalitis diagnosis, and of those, 286 patients with true autoimmune encephalitis were excluded.Main Outcomes and MeasuresData were collected on clinical features, investigations, fulfillment of autoimmune encephalitis criteria, alternative diagnoses, potential contributors to misdiagnosis, and immunotherapy adverse reactions.ResultsA total of 107 patients were misdiagnosed with autoimmune encephalitis, and 77 (72%) did not fulfill diagnostic criteria for autoimmune encephalitis. The median (IQR) age was 48 (35.5-60.5) years and 65 (61%) were female. Correct diagnoses included functional neurologic disorder (27 [25%]), neurodegenerative disease (22 [20.5%]), primary psychiatric disease (19 [18%]), cognitive deficits from comorbidities (11 [10%]), cerebral neoplasm (10 [9.5%]), and other (18 [17%]). Onset was acute/subacute in 56 (52%) or insidious (&amp;gt;3 months) in 51 (48%). Magnetic resonance imaging of the brain was suggestive of encephalitis in 19 of 104 patients (18%) and cerebrospinal fluid (CSF) pleocytosis occurred in 16 of 84 patients (19%). Thyroid peroxidase antibodies were elevated in 24 of 62 patients (39%). Positive neural autoantibodies were more frequent in serum than CSF (48 of 105 [46%] vs 7 of 91 [8%]) and included 1 or more of GAD65 (n = 14), voltage-gated potassium channel complex (LGI1 and CASPR2 negative) (n = 10), N-methyl-d-aspartate receptor by cell-based assay only (n = 10; 6 negative in CSF), and other (n = 18). Adverse reactions from immunotherapies occurred in 17 of 84 patients (20%). Potential contributors to misdiagnosis included overinterpretation of positive serum antibodies (53 [50%]), misinterpretation of functional/psychiatric, or nonspecific cognitive dysfunction as encephalopathy (41 [38%]).Conclusions and RelevanceWhen evaluating for autoimmune encephalitis, a broad differential diagnosis should be considered and misdiagnosis occurs in many settings including at specialized centers. In this study, red flags suggesting alternative diagnoses included an insidious onset, positive nonspecific serum antibody, and failure to fulfill autoimmune encephalitis diagnostic criteria. Autoimmune encephalitis misdiagnosis leads to morbidity from unnecessary immunotherapies and delayed treatment of the correct diagnosis.
660 Clinicopathologic characteristics of patients with metastatic colorectal cancer with molecular responses following treatment with an individualized neoantigen vaccine regimen
Liao, Chih‐Yi , Henick, Brian S. , Overman, Michael J. , Polite, Blasé N. , Roychowdhury, Sameek , Ahn, Daniel H. , Johnson, Melissa M., Schenk, Desiree, Bae, Kyounghwa, Jooss, Karin , Johnson, Benny , Spira, Alexander I. , Carbone, David Paul , Mahipal, Amit , Johnson, Melissa, Davis, Matthew M. , Ferguson, Andrew, Solomon, Benjamin

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: A691-A691

10.1136/jitc-2022-sitc2022.0660 Get It

Metabolome-wide association study on ABCA7 indicates a role of ceramide metabolism in Alzheimer’s disease
Dehghan, Abbas , Pinto, Rui , Karaman, İbrahim , Huang, Jian , Durainayagam, Brenan R., Ghanbari, Mohsen , Nazeer, Areesha , Zhong, Qi , Whiley, Luke , Mustafa, Rima , Solomon, Alina , Ngandu, Tiia , Kanekiyo, Takahisa , Aikawa, Tomonori , Radulescu, Carola I. , Graça, Gonçalo , Camuzeaux, Stéphane , Kaluarachchi, Manuja , Holmes, Elaine , Griffin, Julian L. , Whiley, Luke , Mustafa, Rima , Kanekiyo, Takahisa , Aikawa, Tomonori , Barnes, Samuel J , Chekmeneva, Elena , Kaluarachchi, Manuja R , Holmes, Elaine , Matthews, Paul M , Elliott, Paul , Zhong, Qi , Liggi, Sonia , Kivipelto, Miia , Lewis, Matthew R , Ikram, M. Arfan , Tzoulaki, Ioanna , Matthews, Paul M.

Mayo Clinic

Proceedings of the National Academy of Sciences | October 21, 2022 | Volume: 119 | Issue: 43 | Pages: No page available

10.1073/pnas.2206083119 | PMID 36269859 Get It

Genome-wide association studies (GWASs) have identified genetic loci associated with the risk of Alzheimer’s disease (AD), but the molecular mechanisms by which they confer risk are largely unknown. We conducted a metabolome-wide association study (MWAS) of AD-associated loci from GWASs using untargeted metabolic profiling (metabolomics) by ultraperformance liquid chromatography–mass spectrometry (UPLC-MS). We identified an association of lactosylceramides (LacCer) with AD-related single-nucleotide polymorphisms (SNPs) in ABCA7 ( P = 5.0 × 10 −5 to 1.3 × 10 −44 ). We showed that plasma LacCer concentrations are associated with cognitive performance and genetically modified levels of LacCer are associated with AD risk. We then showed that concentrations of sphingomyelins, ceramides, and hexosylceramides were altered in brain tissue from Abca7 knockout mice, compared with wild type (WT) ( P = 0.049–1.4 × 10 −5 ), but not in a mouse model of amyloidosis. Furthermore, activation of microglia increases intracellular concentrations of hexosylceramides in part through induction in the expression of sphingosine kinase, an enzyme with a high control coefficient for sphingolipid and ceramide synthesis. Our work suggests that the risk for AD arising from functional variations in ABCA7 is mediated at least in part through ceramides. Modulation of their metabolism or downstream signaling may offer new therapeutic opportunities for AD.
Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL
Abramson, Jeremy S. , Johnston, Patrick B. , Ibrahimi, Sami , Arnason, Jon , Glaß, Bertram , Mutsaers, Pim , Lunning, Matthew A. , Braverman, Julia , Liu, Fei Fei , Crotta, Alessandro, Montheard, Sandrine, Previtali, Alessandro , Guo, Shien, Shi, Ling , Solomon, Scott R. , Liu, Fei Fei , Abramson, Jeremy S , Ibrahimi, Sami , Kamdar, Manali , Izutsu, Koji

Mayo Clinic

Blood Advances | September 23, 2022 | Volume: 6 | Issue: 23 | Pages: 5969-5979

10.1182/bloodadvances.2022008106 | PMID 36149968 Get It

Abstract Lisocabtagene maraleucel (liso-cel) has shown promising efficacy in clinical trials for patients with relapsed/refractory large B-cell lymphoma (LBCL). We present health-related quality of life (HRQOL) results from the TRANSFORM study, the first comparative analysis of liso-cel vs standard of care (SOC) as second-line therapy in this population. Adults with LBCL refractory or relapsed ≤12 months after first-line therapy and eligible for autologous stem cell transplantation were randomized 1:1 to the liso-cel or SOC arms (3 cycles of immunochemotherapy in which responders proceeded to high-dose chemotherapy and autologous stem cell transplantation). HRQOL was assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire – 30 items and the Functional Assessment of Cancer Therapy-Lymphoma subscale. Patients with baseline and ≥1 postbaseline assessment were analyzed (liso-cel, n = 47; SOC, n = 43). The proportion of patients with meaningful improvement in global health status/quality of life (QOL) was higher, whereas deterioration was lower in the liso-cel arm vs SOC arm from day 126 to month 6. Mean change scores showed meaningful worsening in global health status/QOL at month 6, fatigue at day 29 and month 6, and pain at month 6 with SOC; mean scores for other domains were maintained or improved in both arms. Time to confirmed deterioration favored the liso-cel arm vs SOC arm in global health status/QOL (median: not reached vs 19.0 weeks, respectively; hazard ratio, 0.47; 95% confidence interval, 0.24-0.94). HRQOL was either improved or maintained from baseline in patients with relapsed/refractory LBCL in the liso-cel arm vs SOC arm as second-line treatment. This study is registered at clinicaltrials.gov as #NCT0357531.
Whole-exome Sequencing of Nigerian Prostate Tumors from the Prostate Cancer Transatlantic Consortium (CaPTC) Reveals DNA Repair Genes Associated with African Ancestry
White, Jason , Kaninjing, Ernest , Adeniji, Kayode , Jibrin, Paul, Obafunwa, John , Ogo, Chidiebere, Faruk, Mohammed , Popoola, Ademola , Fatiregun, Omolara , Oluwole, Olabode P., Karanam, Balasubramanyam , Polak, Paz , Brignole, Kathryn R. , Dean‐Colomb, Windy, Odedina, Folake T., Martin, Damali N. , Yates, Clayton , White, Jason A , Kaninjing, Ernest T , Obafunwa, John O , Mohammed, Faruk , Elhussin, Isra , Ambs, Stefan , Tang, Wei , Davis, Melissa , Campbell, Moray J , Brignole, Kathryn R , Odedina, Folakemi , Yates, Clayton , Popoola, Ademola A , Fatiregun, Omolara , Campbell, Moray J. , Rotimi, Solomon O.

Mayo Clinic

Cancer Research Communications | September 16, 2022 | Volume: 2 | Issue: 9 | Pages: 1005-1016

10.1158/2767-9764.crc-22-0136 | PMID 36922933 Get It

In this study, we used whole-exome sequencing of a cohort of 45 advanced-stage, treatment-naïve Nigerian (NG) primary prostate cancer tumors and 11 unmatched nontumor tissues to compare genomic mutations with African American (AA) and European American (EA) The Cancer Genome Atlas (TCGA) prostate cancer. NG samples were collected from six sites in central and southwest Nigeria. After whole-exome sequencing, samples were processed using GATK best practices. BRCA1 (100%), BARD1 (45%), BRCA2 (27%), and PMS2(18%) had germline alterations in at least two NG nontumor samples. Across 111 germline variants, the AA cohort reflected a pattern [BRCA1 (68%), BARD1 (34%), BRCA2 (28%), and PMS2 (16%)] similar to NG samples. Of the most frequently mutated genes, BRCA1 showed a statistically (P ≤ 0.05) higher germline mutation frequency in men of African ancestry (MAA) and increasing variant frequency with increased African ancestry. Disaggregating gene-level mutation frequencies by variants revealed both ancestry-linked and NG-specific germline variant patterns. Driven by rs799917 (T&gt;C), BRCA1 showed an increasing mutation frequency as African ancestry increased. BRCA2_rs11571831 was present only in MAA, and BRCA2_rs766173 was elevated in NG men. A total of 133 somatic variants were present in 26 prostate cancer–associated genes within the NG tumor cohort. BRCA2 (27%), APC (20%), ATM (20%), BRCA1 (13%), DNAJC6 (13%), EGFR (13%), MAD1L1 (13%), MLH1 (11%), and PMS2 (11%) showed mutation frequencies &gt;10%. Compared with TCGA cohorts, NG tumors showed statistically significant elevated frequencies of BRCA2, APC, and BRCA1. The NG cohort variant pattern shared similarities (cosign similarities ≥0.734) with Catalogue of Somatic Mutations in Cancer signatures 5 and 6, and mutated genes showed significant (q &lt; 0.001) gene ontology (GO) and functional enrichment in mismatch repair and non-homologous repair deficiency pathways. Here, we showed that mutations in DNA damage response genes were higher in NG prostate cancer samples and that a portion of those mutations correlate with African ancestry. Moreover, we identified variants of unknown significance that may contribute to population-specific routes of tumorigenesis and treatment. These results present the most comprehensive characterization of the NG prostate cancer exome to date and highlight the need to increase diversity of study populations. Significance: MAA have higher rates of prostate cancer incidence and mortality, however, are severely underrepresented in genomic studies. This is the first study utilizing whole-exome sequencing in NG men to identify West African ancestry-linked variant patterns that impact DNA damage repair pathways.
A Simple Score to Identify Increased Risk of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction
Davies, Daniel R. , Redfield, Margaret M. , Minamisawa, Masatoshi, Grogan, Martha , Shah, Amil M. , Wehbe, Ramsey M. , Solomon, Scott D. , Reddy, Yogesh N.V. , AbouEzzeddine, Omar F. , Nishimura, Rick , Shah, Amil , AbouEzzeddine, Omar F , Scott, Christopher G. , Dispenzieri, Angela , Chareonthaitawee, Panithaya , Shah, Sanjiv J , Solomon, Scott David , Borlaug, Barry A.

Mayo Clinic

JAMA Cardiology | September 7, 2022 | Volume: 7 | Issue: 10 | Pages: 1036

10.1001/jamacardio.2022.1781 | PMID 36069809 Get It

ImportanceTransthyretin amyloid cardiomyopathy (ATTR-CM) is a form of heart failure (HF) with preserved ejection fraction (HFpEF). Technetium Tc 99m pyrophosphate scintigraphy (PYP) enables ATTR-CM diagnosis. It is unclear which patients with HFpEF have sufficient risk of ATTR-CM to warrant PYP.ObjectiveTo derive and validate a simple ATTR-CM score to predict increased risk of ATTR-CM in patients with HFpEF.Design, Setting, and ParticipantsRetrospective cohort study of 666 patients with HF (ejection fraction ≥ 40%) and suspected ATTR-CM referred for PYP at Mayo Clinic, Rochester, Minnesota, from May 10, 2013, through August 31, 2020. These data were analyzed September 2020 through December 2020. A logistic regression model predictive of ATTR-CM was derived and converted to a point-based ATTR-CM risk score. The score was further validated in a community ATTR-CM epidemiology study of older patients with HFpEF with increased left ventricular wall thickness ([WT] ≥ 12 mm) and in an external (Northwestern University, Chicago, Illinois) HFpEF cohort referred for PYP. Race was self-reported by the participants. In all cohorts, both case patients and control patients were definitively ascertained by PYP scanning and specialist evaluation.Main Outcomes and MeasuresPerformance of the derived ATTR-CM score in all cohorts (referral validation, community validation, and external validation) and prevalence of a high-risk ATTR-CM score in 4 multinational HFpEF clinical trials.ResultsParticipant cohorts included were referral derivation (n = 416; 13 participants [3%] were Black and 380 participants [94%] were White; ATTR-CM prevalence = 45%), referral validation (n = 250; 12 participants [5%]were Black and 228 participants [93%] were White; ATTR-CM prevalence = 48% ), community validation (n = 286; 5 participants [2%] were Black and 275 participants [96%] were White; ATTR-CM prevalence = 6% ), and external validation (n = 66; 23 participants [37%] were Black and 36 participants [58%] were White; ATTR-CM prevalence = 39%). Score variables included age, male sex, hypertension diagnosis, relative WT more than 0.57, posterior WT of 12 mm or more, and ejection fraction less than 60% (score range −1 to 10). Discrimination (area under the receiver operating characteristic curve [AUC] 0.89; 95% CI, 0.86-0.92; P &amp;lt; .001) and calibration (Hosmer-Lemeshow; χ2 = 4.6; P = .46) were strong. Discrimination (AUC ≥ 0.84; P &amp;lt; .001 for all) and calibration (Hosmer-Lemeshow χ2 = 2.8; P = .84; Hosmer-Lemeshow χ2 = 4.4; P = .35; Hosmer-Lemeshow χ2 = 2.5; P = .78 in referral, community, and external validation cohorts, respectively) were maintained in all validation cohorts. Precision-recall curves and predictive value vs prevalence plots indicated clinically useful classification performance for a score of 6 or more (positive predictive value ≥25%) in clinically relevant ATTR-CM prevalence (≥10% of patients with HFpEF) scenarios. In the HFpEF clinical trials, 11% to 35% of male and 0% to 6% of female patients had a high-risk (≥6) ATTR-CM score.Conclusions and RelevanceA simple 6 variable clinical score may be used to guide use of PYP and increase recognition of ATTR-CM among patients with HFpEF in the community. Further validation in larger and more diverse populations is needed.
Critical Care Cardiology Trials Network (CCCTN): a cohort profile
Metkus, Thomas S. , Baird-Zars, Vivian M., Alfonso, Carlos E., Alviar, Carlos L. , Barsness, Gregory W. , Bertić, Mia , Bohula, Erin A. , Burke, James A. , Burstein, Barry , Cooper, Howard A., Daniels, Lori B. , Goldfarb, Michael , Katz, Jason N. , Keeley, Ellen C. , Keller, Norma, Kenigsberg, Benjamin B. , Kontos, Michael C. , Lawler, Patrick R. , Leibner, Evan , Menon, Venu , Miller, P. Elliott , Newby, L. Kristin , O’Brien, Connor , Papolos, Alexander , Pierce, Matthew J, Prasad, Rajnish, Pisani, Barbara , Smith, Timothy D., Snell, R. Jeffrey, So, Derek , Ternus, Bradley , Teuteberg, Jeffrey J. , Zakaria, Sammy , Goldfarb, Michael , Pierce, Matthew , Fordyce, Christopher B , Goldfarb, Michael , Solomon, Michael A , van Diepen, Sean , Goldfarb, Michael , Lawler, Patrick , Daniels, Lori B , Bohula, Erin A , Zakaria, Sammy , O'Brien, Connor G , Pierce, Matthew J , Barnett, Christopher F. , Berg, David D. , Burke, James, Chaudhry, Sunit‐Preet , Fordyce, Christopher B. , Ghafghazi, Shahab , Kwon, Younghoon, Liu, Shuangbo , Prasad, Rajnish, Potter, Brian J , Roswell, Robert O. , Sinha, Shashank S , Shah, Kevin S , Solomon, Michael A. , Diepen, Sean van , Morrow, David A.

Mayo Clinic

European Heart Journal - Quality of Care and Clinical Outcomes | August 27, 2022 | Volume: 8 | Issue: 7 | Pages: 703-708

10.1093/ehjqcco/qcac055 | PMID 36029517 Get It

AbstractAimsThe aims of the Critical Care Cardiology Trials Network (CCCTN) are to develop a registry to investigate the epidemiology of cardiac critical illness and to establish a multicentre research network to conduct randomised clinical trials (RCTs) in patients with cardiac critical illness.Methods and resultsThe CCCTN was founded in 2017 with 16 centres and has grown to a research network of over 40 academic and clinical centres in the United States and Canada. Each centre enters data for consecutive cardiac intensive care unit (CICU) admissions for at least 2 months of each calendar year. More than 20 000 unique CICU admissions are now included in the CCCTN Registry. To date, scientific observations from the CCCTN Registry include description of variations in care, the epidemiology and outcomes of all CICU patients, as well as subsets of patients with specific disease states, such as shock, heart failure, renal dysfunction, and respiratory failure. The CCCTN has also characterised utilization patterns, including use of mechanical circulatory support in response to changes in the heart transplantation allocation system, and the use and impact of multidisciplinary shock teams. Over years of multicentre collaboration, the CCCTN has established a robust research network to facilitate multicentre registry-based randomised trials in patients with cardiac critical illness.ConclusionThe CCCTN is a large, prospective registry dedicated to describing processes-of-care and expanding clinical knowledge in cardiac critical illness. The CCCTN will serve as an investigational platform from which to conduct randomised controlled trials in this important patient population.